NO20052478L - Vitamin D-analoger, sammensetninger omfattende analogene og deres anvendelse. - Google Patents

Vitamin D-analoger, sammensetninger omfattende analogene og deres anvendelse.

Info

Publication number
NO20052478L
NO20052478L NO20052478A NO20052478A NO20052478L NO 20052478 L NO20052478 L NO 20052478L NO 20052478 A NO20052478 A NO 20052478A NO 20052478 A NO20052478 A NO 20052478A NO 20052478 L NO20052478 L NO 20052478L
Authority
NO
Norway
Prior art keywords
bond
hydrogen
ethylene
proviso
represent
Prior art date
Application number
NO20052478A
Other languages
English (en)
Other versions
NO20052478D0 (no
Inventor
Martin John Calverley
Ernst Torndal Binderup
Kai Holst Hansen
Claus Aage Svensgaard Bretting
Original Assignee
Leo Pharma As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Leo Pharma As filed Critical Leo Pharma As
Publication of NO20052478D0 publication Critical patent/NO20052478D0/no
Publication of NO20052478L publication Critical patent/NO20052478L/no

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C401/00Irradiation products of cholesterol or its derivatives; Vitamin D derivatives, 9,10-seco cyclopenta[a]phenanthrene or analogues obtained by chemical preparation without irradiation
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/59Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/59Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A61K31/5939,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/10Anti-acne agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/14Drugs for dermatological disorders for baldness or alopecia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/16Emollients or protectives, e.g. against radiation
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/18Drugs for disorders of the endocrine system of the parathyroid hormones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/18Drugs for disorders of the endocrine system of the parathyroid hormones
    • A61P5/20Drugs for disorders of the endocrine system of the parathyroid hormones for decreasing, blocking or antagonising the activity of PTH
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Communicable Diseases (AREA)
  • Obesity (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Psychiatry (AREA)
  • Transplantation (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • AIDS & HIV (AREA)
  • Emergency Medicine (AREA)

Abstract

Forbindelser i henhold til formel I, i hvilken formel Rl og R2, som kan være det samme eller forskjellige, representerer halogen, (Cl-C6)hydrokarbonyl, eventuelt substituert med én eller to hydroksylgrupper eller ett eller flere fluoratomer, eller, sammen med karbonatomet til hvilket de begge er bundet, danner Rl og R2 en (C3-C6)karbocyklisk ring, eller én av Rl og R2 tatt sammen med R3 danner en direktebinding, slik at en trippelbinding dannes, eller Rl og R2 representerer begge hydrogen; R3 når den ikke danner en direktebinding med én av Rl og R2 representerer hydrogen eller (Cl-C3)hydrokarbonyl; X representerer (E)-etylen, (Z)-etylen, etynylen eller en binding; Y og Z representerer uavhengig hydrogen eller metyl; bindingen mellom C#16 og C#17 er tegnet med en stiplet linje for å illustrere at bindingen kan være enten en enkeltbinding, i hvilket tilfelle projeksjonen av ringsubstituenten er beta, eller en dobbeltbinding; A representerer hydroksyl, fluor eller hydrogen; B representerer CH2 eller H2; konfigurasjonen i 3-stillingen tilsvarer den samme konfigurasjon som i naturlig vitamin D3 (normal), eller konfigurasjonen i 3-stillingen er motsatt av den i naturlig vitamin D3 (epi); med det forbehold at når X representerer (E)-etylen eller (Z)-etylen, kan én av Rl og R2 tatt sammen med R3 ikke danne en direktebinding, slik at en trippelbinding dannes; med det ytterligere forbehold at når X representerer en binding er Rl og R2 ikke hydrogen; med det ytterligere forbehold at forbindelsen med formel l ikke er 3(S)-hydroksy-9,10secokolesta-5(Z),7(E),10(19), 22(E),24-penta-en; og prodruger og stereoisomere former derav tilveiebringes sammen med deres anvendelse i terapi, og deres anvendelse i fremstillingen av medikamenter.
NO20052478A 2002-10-23 2005-05-23 Vitamin D-analoger, sammensetninger omfattende analogene og deres anvendelse. NO20052478L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DKPA200201608 2002-10-23
US42078302P 2002-10-24 2002-10-24
PCT/DK2003/000718 WO2004037781A1 (en) 2002-10-23 2003-10-23 Vitamin d analogues, compositions comprising said analogues and their use

Publications (2)

Publication Number Publication Date
NO20052478D0 NO20052478D0 (no) 2005-05-23
NO20052478L true NO20052478L (no) 2005-05-23

Family

ID=32178574

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20052478A NO20052478L (no) 2002-10-23 2005-05-23 Vitamin D-analoger, sammensetninger omfattende analogene og deres anvendelse.

Country Status (12)

Country Link
EP (1) EP1556345B1 (no)
JP (1) JP4512490B2 (no)
KR (1) KR20050055784A (no)
AU (1) AU2003273781B2 (no)
BR (1) BR0315553A (no)
CA (1) CA2500640A1 (no)
IS (1) IS7835A (no)
MX (1) MXPA05003499A (no)
NO (1) NO20052478L (no)
PL (1) PL376148A1 (no)
RU (1) RU2320644C2 (no)
WO (1) WO2004037781A1 (no)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2233209B1 (es) * 2003-11-28 2006-04-01 Laboratorios Viñas S.A. Compuestos monohalogenovinilderivados de vitamina d.
KR20070056001A (ko) * 2004-04-02 2007-05-31 레오 파마 에이/에스 비타민 d 동족체의 합성에 유용한 중간체의 신규한제조방법
ES2406735T3 (es) * 2006-03-17 2013-06-07 Leo Pharma A/S Isomerización de compuestos intermedios farmacéuticos
EP2464357B1 (en) * 2009-08-14 2019-05-22 Berg LLC Vitamin d3 and analogs thereof for treating alopecia
WO2011088209A2 (en) * 2010-01-13 2011-07-21 Cytochroma Inc. 1-deoxy analogs of vitamin d-related compounds
ES2386219B1 (es) * 2010-12-28 2013-06-24 Laboratorios Viñas S.A. Procedimiento para isomerizar c-22 iodovinilderivados por fotoisomerización.
CN103508999B (zh) * 2013-10-12 2015-05-13 浙江海正药业股份有限公司 马沙骨化醇的合成中间体及其制备方法和用途
CN104693087A (zh) * 2013-12-10 2015-06-10 南京理工大学 24,28-烯-1α-羟基维生素D类衍生物及其制备方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8915770D0 (en) * 1989-07-10 1989-08-31 Leo Pharm Prod Ltd Chemical compounds
GB9017890D0 (en) * 1990-08-15 1990-09-26 Leo Pharm Prod Ltd Chemical compounds i
GB9314400D0 (en) * 1993-07-12 1993-08-25 Leo Pharm Prod Ltd Produktionsaktieselskab) chemical compounds
ATE290526T1 (de) * 1997-06-25 2005-03-15 Teijin Ltd Vitamin-d3?-derivate und aus diesen hergestellte heilmittel gegen entzündliche erkrankungen der atemwege
US5972917A (en) * 1998-05-29 1999-10-26 Bone Care Int Inc 1 α-hydroxy-25-ene-vitamin D, analogs and uses thereof
CA2420759A1 (en) * 2000-08-30 2003-02-27 Daishiro Miura Parathyroid hormone production inhibitors containing vitamin d3 derivatives
KR100628586B1 (ko) * 2001-09-21 2006-09-26 에프. 호프만-라 로슈 아게 3-데속시-비타민 디3 유사 에스테르

Also Published As

Publication number Publication date
JP2006503880A (ja) 2006-02-02
MXPA05003499A (es) 2005-06-17
AU2003273781B2 (en) 2010-04-29
PL376148A1 (en) 2005-12-27
KR20050055784A (ko) 2005-06-13
RU2005115482A (ru) 2005-11-10
BR0315553A (pt) 2005-08-23
NO20052478D0 (no) 2005-05-23
EP1556345B1 (en) 2010-12-15
RU2320644C2 (ru) 2008-03-27
IS7835A (is) 2005-05-03
CA2500640A1 (en) 2004-05-06
JP4512490B2 (ja) 2010-07-28
EP1556345A1 (en) 2005-07-27
AU2003273781A1 (en) 2004-05-13
WO2004037781A1 (en) 2004-05-06

Similar Documents

Publication Publication Date Title
MX2022005399A (es) Compuestos.
NO20015655D0 (no) Indol-type derivater som inhibitorer av p38 kinase
DK1697371T3 (da) Azabicykliske heterocykliske forbindelser som cannabinoidreceptormodulatorer
NO20081593L (no) Depotsammensetning
MX9804105A (es) Antagonistas de taquicininas a base de piperidonas.
NO20062689L (no) Azabisykliske heterosykler som modulatorer for kannabinoidreseptorer
MX2023009045A (es) Derivados novedosos de pirimidin-2-il sulfonamida.
MY117783A (en) Halogen substituted tetracyclic tetrahydrofuran derivatives
ATE135348T1 (de) Pyrimidin-4-carboxamidderivate, ihre herstellung und ihre verwendung in der therapie
MX2020010433A (es) Compuestos de pirazol sustituidos con heteroarilo y uso farmaceutico de los mismos.
NO20052074L (no) Substituerte benzoksazinoner og anvendelser derav.
TW200612920A (en) Novel imidazolidine derivatives
UY27979A1 (es) Indoles sustituidos en posición 2,4
UY27980A1 (es) Indoles 2,7-sustituidos
MY146939A (en) Derivatives of 7-alkynyl-1,8-naphthyridones, preparation method thereof and use of same in therapeutics
MX2025002166A (es) Compuestos y metodos para modular her2
MX2025001765A (es) Derivados deuterados de pirimidin-2-il sulfonamida
NO20062491L (no) Benzoksazinderivter og deres anvendelse
AU1274495A (en) Unsaturate amino compounds for use as anticancer and antiprotozoic agent
WO2004098507A3 (en) 1,3 aclyated 24-keto-vitamin d3 compounds and methods of use thereof
DE60328819D1 (de) Indol-3-carboxamide, deren herstellung und therapeutische verwendung
ATE458744T1 (de) NEUE 2-SUBSTITUIERTE D-HOMO ESTRA-1,3,5(10)- TRIENE ALS INHIBITOREN DER 17ß- HYDROXYSTEROIDDEHYDROGENASE TYP 1
WO2004028455A3 (en) Monoacylated betulin and dihydrobetulin derivatives, preparation thereof and use thereof
FI884088A0 (fi) Foerfarande foer framstaellning av 17-substituerade androsta-1,4-dien-3-onderivat.
AU4530693A (en) Cyanoguanidines as potassium channel blockers

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application